Published in Gastroenterology Week, April 21st, 2008
"A significant amount of time and money is spent annually on alternative therapies such as Omega-3 fatty acids, without strong evidence that they are beneficial to patients with inflammatory bowel disease," says gastroenterologist Dr. Feagan, who is Director of Robarts Clinical Trials and lead author on the study. "I encourage Crohn's patients to focus on prescription...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gastroenterology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.